Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wataru Kamata

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
International Journal of Hematology|September 19, 2020
Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agentsShuku Sato, Wataru Kamata, Satomi Okada, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 6, 2021
[Prognostic factors in light-chain cardiac amyloidosis: a retrospective analysis]Hiroki Okumura, Shuku Sato, Wataru Kamata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 7, 2022
[Plasmablastic myeloma initially presented with ascites]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Ejhaem|February 26, 2024
From primary myelofibrosis to chronic myeloid leukemia, <i>BCR::ABL1</i>+ B-Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolutionDevin Wang, Wataru Kamata, Fengxi Ye, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 5, 2025
[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Annals of Hematology|March 23, 2023
Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myelomaShuku Sato, Shun Tsunoda, Teiko Kawahigashi, et al.
Blood Research|February 5, 2025
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysisShuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Frontiers in Medicine|June 20, 2022
Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia AreataYotaro Tamai, Shinichi Teshima, Shun Tsunoda, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 14, 2025
Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty ScoreShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Journal of Cardiology Cases|August 11, 2020
Insight from an autopsy in a patient with rapidly worsening heart failure due to amyloid light-chain cardiac amyloidosis: A case reportHiroaki Yokoyama, Koki Shishido, Junko Ito, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
International Journal of Hematology|September 19, 2020
Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agentsShuku Sato, Wataru Kamata, Satomi Okada, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|December 6, 2021
[Prognostic factors in light-chain cardiac amyloidosis: a retrospective analysis]Hiroki Okumura, Shuku Sato, Wataru Kamata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 7, 2022
[Plasmablastic myeloma initially presented with ascites]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Ejhaem|February 26, 2024
From primary myelofibrosis to chronic myeloid leukemia, <i>BCR::ABL1</i>+ B-Lymphoblastic leukemia, and back to primary myelofibrosis: An illustration of dynamic clonal evolutionDevin Wang, Wataru Kamata, Fengxi Ye, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 5, 2025
[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Annals of Hematology|March 23, 2023
Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myelomaShuku Sato, Shun Tsunoda, Teiko Kawahigashi, et al.
Blood Research|February 5, 2025
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysisShuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Frontiers in Medicine|June 20, 2022
Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia AreataYotaro Tamai, Shinichi Teshima, Shun Tsunoda, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 14, 2025
Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty ScoreShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Journal of Cardiology Cases|August 11, 2020
Insight from an autopsy in a patient with rapidly worsening heart failure due to amyloid light-chain cardiac amyloidosis: A case reportHiroaki Yokoyama, Koki Shishido, Junko Ito, et al.
Pageof 2